Eurochap2010 final program

IN CONJUNCTION WITH
9th World Congress for Microcirculation
Maison de la Chimie, September 26-28, 2010

9th Annual Congress of the « Société Française de Médecine Vasculaire »
La Villette, September 23-25, 2010

UNDER THE AUSPICES OF
Société Française de Médecine Vasculaire (SFMV)

Société de Chirurgie Vasculaire de Langue Française (SCVLF)

Société Française d’Angiologie (SFA)

Collège Français de Pathologie Vasculaire (CFPV)

Collège des Enseignants de Médecine Vasculaire (CEMV)

ACKNOWLEDGMENTS
The International Union of Angiology thanks for their participation

Ad Rem Technology

2~

WELCOME ADDRESS
Dear Participant,

On behalf of the European Chapter of the International Union of Angiology,
and the French societies of vascular medicine and surgery, I am very pleased
to offer you a warm welcome to the 19th Eurochap!

The special position of this additional congress allowed us to experiment
some specific features, organized in a compact form with only two parallel
rooms:
- short lectures keeping time for discussions are organized in thematic symposia addressing the
changes in concepts and practices in the different vascular fields;
- specific postgraduate sessions based on clinical case solving and decision making will use
electronic votes in addition to the comments of experts, in order to increase interactivity;
- and the “Forum of Vascular Initiatives”, which will be an occasion to share the richness of
the initiatives of the IUA and its members for the teaching of vascular medicine and surgery,
the quality of care for the vascular patients and the promotion of patients associations and even
humanitarian actions.
The innovations also take a great part, since our congress attracted many proposals from
which we were able to select 150 abstracts organized in seven oral and ten poster sessions
with discussion rounds; furthermore the last congress day will be shared with the 9th World
Congress for Microcirculation that follows in the same location.

As you can see, everything has been thought in order to promote and facilitate scientific exchange
in a positive and friendly atmosphere. Many top scientist and physicians invited from all over
Europe and abroad accepted to play the game with you according to these principles, and we
need you to be as active as possible in order to get as much as you can from the feast!

As the congress takes place in the Maison de la Chimie, in the historical center of Paris, we
hope it will also be for you the occasion to enjoy the cultural wealth of Paris.

For the Organizing Committee,

Professor Patrick Carpentier, President

SUMMARY
Synopsis .................................................................................... 4
Scientific Program
Friday, September 24 ............................................................. 7
Saturday, September 25 ......................................................... 14
Sunday, September 26 ........................................................... 20
Congress Map and Exhibition Plan ......................................... 24
Abstracts
Symposia .............................................................................. 26
Oral Communications ......................................................... 43
Posters ................................................................................. 58
Authors’ Index .......................................................................... 85
General Information ................................................................. 89

www.iua-eurochap2010.eu ~ 3

sYNOPSIS
Friday, September 24, 2010
From 07:45 registration Hall 28 bis

08:30-09:20 amphithéâtre Lavoisier
Plenary lecture
the 2010 milestones of the vascular surgeon
J. Fernandes e Fernandes
09:30-11:00 amphithéâtre Lavoisier petit amphithéâtre
SY1 - Symposium SY2 - Corporate Symposium SIGVARIS
abdominal aortic aneurysms: an update Efficient compression therapy to treat venous diseases:
scientific, medical and practical key factors
11:00-11:30 Coffee break - Posters and Exhibition visit Room 8
SY3 - Symposium OC1 - Free communications
Carotid stenosis: moving concepts and practices Vascular surgery: arteries
13:00-14:00 Break - Posters and Exhibition visit Room 8
14:00-15:30 amphithéâtre Lavoisier petit amphithéâtre room 8
SY4 - Symposium OC2 - Free communications poster Sessions
early detection peripheral arterial disease pS1 to pS5
of the high vascular risk subjects
Therapeutic education of the vascular patient Venous thromboembolic disease
SY6 - Corporate symposium SY7 - Symposium
Cook Medical New insights about the calf muscle pump function
New developments in endovascular technologies Organized thanks to an unrestricted grant
from Ad Rem Technology - Veinoplus

SatUrday, September 25, 2010
Plenary lecture
the 2010 milestones of the vascular physician
J. Belch
SY8 - Symposium Postgraduate Course
Venous thromboembolic disease: Leg and foot ulcers - Critical limb ischemia
moving concepts and practices
Organized thanks to an unrestricted grant from Eumedica
SY9 - Symposium Postgraduate Course
Varicose vein treatment in the future Venous thromboembolic disease - thrombophilia
13:00-14:00 Break - Posters and Exhibition visit Room 8
SY10 - Symposium Postgraduate Course poster Sessions
Ultrasound guided procedures Clinical microcirculation pS6 to pS9
Plenary session
Forum of vascular initiatives

19:30 Congress dinner at the Cercle National des Armées (under registration)

Pleanary session
Symposia and free communications
4~
Posters

sYNOPSIS
SUNday, September 26, 2010
09:30-11:00 petit amphithéâtre room 262
SY11 - Joint Symposium with the OC4 - Free communications
Italian Society of Angiology and Vascular Medicine Varicose veins
physical exercise and vascular medicine
11:00-11:30 Coffee break - Exhibition visit Room 8
11:30-13:00 petit amphithéâtre room 262
From raynaud phenomenon to digital ulcer atherosclerosis
Organized thanks to an unrestricted educational grant
from Actelion Pharmaceuticals

13:00-14:00 Break - Exhibition visit Room 8
SY13 - Symposium SY14 - Joint Symposium with the OC6 - Free communications
Critical limb ischemia Romanian Society of Angiology and rare vascular diseases and progress
Organized thanks to an unrestricted grant Vascular Surgery in vascular diagnosis
from Sanofi Aventis Complications of vascular procedures
15:30-16:00 Break - Exhibition visit Room 8
16:00-17:30 amphithéâtre Lavoisier room 262
SY15 - Joint Symposium EuroChap - Microcirculation OC7 - Free communications
relationship between macro and microcirculation Venous disorders

Pleanary session
Symposia and free communications
Posters


ORGANIZING COMMITTEE
LOCAL ORGANIZING COMMITTEE
President: Patrick CArPEntIEr (IUA) Members: François-André ALLAErt (SFA)
François BECKEr (CEMV)
Christian BOISSIEr (IUA)
Michèle CAzAUBOn (SFA)
nabil ChAKFE (SCVLF)
Fabien KOSKAS (SCVLF)
Philippe nICOLInI (SCVLF)
Gilles PErnOd (SFMV)
Pascal PrIOLLEt (CFPV)
Isabelle QUéré (SFMV)
Michel VAySSAIrAt (CFPV)

INTERNATIONAL UNION OF ANGIOLOGY
Executive Board
Honorary president Chapter Secretaries
P. BALAS (Greece) K. KOMORI (Japan)
T. KARPLUS (Australia)
president P.L. ANTIGNANI (Italy)
R. SIMKIN (Argentina) C. GOLDENSTEIN (Argentina)
R. SHEPHERD (USA)
president elect A.S. EL GATIT (Libya)
K. ROZTOCIL (Czech Republic) J. PILAI (Rep. S.Africa)
S. NOVO (Italy)
immediate past president
E. BASTOUNIS (Greece) advisors to the board
F. ALLAERT - C. BAKOYIANNIS - J. BARBOSA
advisors to the president F. BENEDETTI VALENTINI - G. BIASI - D. CLEMENT
C. ALLEGRA (Italy) M. DE CASTRO SILVA - G. DERIU - E. DIAMANTOPOULOS
N. ANGELIDES (Cyprus) K. FILIS - W.R. HIATT - A.T. HIRSCH - D. HOPPENTAEDT
E. ASCHER (USA) A. MANSILHA - G. MARCUCCI - P.G. MATTHEWS
P. CARPENTIER (France) L. NORGREN - Z. PECSVARADY
J. FAREED (USA) M.E. RENNO DE CASTRO SANTOS - A. SCHIRGER
J. FERNANDES E FERNANDES (Portugal) F. SPINELLI - A. VISONA’ - Z.G. WANG - J.H. ULLOA
J. FLETCHER (Australia)
S. GEORGOPOULOS (Greece) representatives of other Societies:
H. GIBBS (Australia) International Union of Phlebology (IUP)
P. GLOVICZKI (USA) A. SCUDERI (Brazil)
Y-Q. GU (China)
E. HUSSEIN (Egypt) Mediterranean League of Angiology and Vascular Surgery
B.B. LEE (USA) (MLAVS)
S. NOVO (Italy) CH. LIAPIS (Greece)
H. PARTSCH (Austria)
Central European Vascular Forum (CEVF)
P. POREDOS (Slovenia)
V. STVRTINOVA (Slovak Rep.)
G. RAO (India)
A. SCUDERI (Brazil) Latin American Venosu Forum (LAVF )
H. SHIGEMATSU (Japan) P. KOMLOS (Brazil)
J. ULLOA (Colombia)
I.A.S.A.C.O
Vice presidents S. NOVO (Italy)
Y-Q. GU (China)
P. VALE (Australia) International Society of Vascular Surgery (ISVS)
K. ROZTOCIL (Czech Republic) F. VEITH (UK)
M. DE CASTRO SILVA (Brazil) Vascular Independent Research & Education European
A. SIDAWY (USA) Organisation (VAS)
E. HUSSEIN (Egypt)
M. CATALANO (Italy)
T. ABDOOL CARRIM (Rep. S. Africa)

Secretary General: A. JAWIEN (Poland)
assoc. Secretary General: P. POREDOS (Slovenia)
treasurer General: J. BELCH (UK)
assoc. treasurer General: G. GEROULAKOS (UK)
6~

Scientific Program - Friday, September 24, 2010

08:30 - 09:20 Plenary lecture Amphitheatre Lavoisier

Chair: P. Carpentier (Grenoble, France)

the 2010 milestones of the vascular surgeon
J. Fernandes e Fernandes (Lisbon, Portugal)

09:30 - 11:00 SY1 - Symposium Amphitheatre Lavoisier

abdominal aortic aneurysms: an update
Chairpersons: P. Gloviczki (Rochester, USA), A. Jawien (Bydgoszcz, Poland)

Sy1-1 s Pathogenesis of the abdominal aortic aneurysm
E. Allaire (Créteil, France)

Sy1-2 s Screening for abdominal aortic aneurysm
J.S. Lindholdt (Viborg, Denmark)

Sy1-3 s The long-term results of EVAR I trial
J.T. Powell (London, UK)

Sy1-4 s Medical approach to the patient with an abdominal aortic aneurysm
F. Becker (Geneva, Switzerland)

09:30 - 11:00 SY2 - Corporate Symposium SIGVARIS Petit Amphithéâtre

Efficient compression therapy to treat venous diseases: scientific, medical and practical key factors
Chairpersons: P. Carpentier (Grenoble, France), P. Kern (Vevey, Switzerland)

Sy2-1 s Compression therapy: a bright future requiring many efforts
P. Carpentier (Grenoble, France)

Sy2-2 s New strategies to improve compliance of compression therapy (20-36 mmHg)
D. Rastel, (Grenoble, France)

Sy2-3 s Compression after sclerotherapy
P. Kern (Vevey, Switzerland)

Sy2-4 s The effects of medical compression stockings on venous anatomy
J.F. Uhl (Paris, France)

11:00 - 11:30 Coffee break - Posters and Exhibition visit Room 8


Carotid stenosis: moving concepts and practices
Chairpersons: E. Bastounis (Athens, Greece), F. Becker (Geneva, Switzerland)

Sy3-1 s The surgical treatment of carotid stenosis: new information from recent trials and what is required
for future studies
J. Fernandes e Fernandes (Lisbon, Portugal)

Sy3-2 s Carotid stenosis: place of carotid stenting
J.L. Mas (Paris, France)

Sy3-3 s Stroke and Thrombolytic therapy: an update
V. Larrue (Toulouse, France)

Sy3-4 s Asymptomatic Carotid Stenosis and Risk Stratification
A. Nicolaides (Nicosia, Cyprus) www.iua-eurochap2010.eu ~ 7

11:30 - 13:00 OC1 - Free Oral Communications - Vascular surgery: arteries Petit Amphithéâtre

Chairpersons: F. Koskas (Paris, France), N. Chakfe (Strasbourg, France)

OC1-1 Symptomatic huge abdominal aortic aneurysms
M. Salem, A. Salem, T. Salem (Alexandria, Egypt)

OC1-2 Minimal incision aortic aneurysm repair: an underutilized but safe technique
M. Kalra, A. Duncan, S. Cha, P. Gloviczki (Rochester, USA)

OC1-3 Prevalence of abdominal aortic aneurysm in screening survey of small town’s residents in northern Poland
A. Jawien, B. Formankiewicz, T. Derezinski, A. Migdalski, R. Piotrowicz, G. Jakubowski (Bydgoszcz,
Poland)

OC1-4 Retrograde trans-popliteal recanalization of the superficial femoral artery: the face-down technique
I. Broutzos, I. Dalainas, K. Moulakakis, N. Ptohis, M. Daskalopoulos,
C. Papasideris, A. Papapetrou, K. Xiromeritis, M. Moschou, E. Avgerinos, T. Giannakopoulos,
N. Kelekis, C. Liapis (Athens, Greece)

OC1-5 Intravenous thrombolysis with recombinant tissue plasminogen activator (rt-PA) in acute lower limb
ischemia
V. Flis, N. Kobilica, A. Bergauer, B. Mrdza, F. Milotic, B. Stirn (Maribor, Slovenia)

OC1-6 Endovascular repair of traumatic aortic rupture: single center experience
N. Melas, A. Giannopoulos, N. Saratzis, A. Saratzis, I. Lazaridis, C. Trigonis, K. Ktenidis, D. Kiskinis
(Thessaloniki, Greece)

OC1-7 Surgical treatment principles in patients with traumatic injuries of main vessels, bone-joints of
extremities
N. Abushov, M. Karimov, G. Tagizade, E. Zakirjayev, E. Aliyev (Baku, Azerbaidjan)

13:00 - 14:00 Break - Posters and Exhibition visit Room 8


Early detection of the high vascular risk subjects
Chairpersons: J. Belch (Dundee, UK), S. Novo (Palermo, Italy)

Sy4-1 s Screening for PAD in the general population
V. Aboyans (Limoges, France)

Sy4-2 s Asymptomatic carotid lesions predict global cardiovascular risk beyond the cards of the risk
S. Novo (Palermo, Italy)

Sy4-3 s Early markers in hypertension: often of vascular origin!
D. Clément (Ghent, Belgium)

Sy4-4 s Atherosclerosis and venous thrombosis - the same disease entity with two different faces
P. Poredos, M.K. Jezovnik (Ljubljana, Slovenia)

14:00 - 15:30 OC2 - Free Oral Communications - peripheral arterial disease Petit Amphithéâtre

Chairpersons: G. Marcucci (Civitavecchia, Italy), M. Catalano (Milan, Italy)

OC2-1 Function of endothelial cells in limb ischemia
R. Proczka, M. Kedzior, P. Jagus, P. Bialek, M. Polanska, M. Postacchini,
I. Postacchini, P. Nitkowski, J. Chorostowska-Wynimko, J. Polanski (Warsaw, Poland)

8~

OC2-2 Does really exist a high risk patient for conventional carotid endarterectomy?
G. Marcucci, F. Accrocca, A. Siani, A.G. Giordano, R. Antonelli (Civitavecchia, Rome, Italy)

OC2-3 High prevalence of peripheral arterial disease: results of the evaluation of ankle/brachial index
in hungarian hypertensives (ERV) screening program
K. Farkas, Z. Jarai, E. Kolossvary, A. Ludanyi, I. Kiss (Budapest, Hungary)

OC2-4 Cronocol implant reduces surgical site infection and improves final outcome in ischemic patients
C. Costa Almeida, L. Reis, L. Carvalho, C. Costa Almeida (Coimbra, Portugal)

OC2-5 European biobank on vascular diseases
M. Catalano, VAS-Scientific Team, VAS-Biobank Working Group (Milan, Italy)

OC2-6 Assessment of collateral blood flow in ischemic lower limb
O. Albazde (London, UK)

OC2-7 Comparative studding of hemorheological indexes in patients with critical limb ischemia
N. Abushov, E. Zakirjayev, Z. Aliyev, G. Zeynalova (Baku, Azerbaijan)

14:00 - 15:30 Posters Sessions - PS1 to PS5 Room 8

Presenting authors are requested to stand close to their poster during the guided visit. Authors will have
4 minutes to present orally their work.
14:00 - 15:30 pS1 - atherosclerosis Room 8

pS1-1 Association between serum uric acid, carotid intima-media thickness and target organ damage
in hypertensive patients
C. Serban, S. Dragan, I. Mozos, R. Mateescu, L. Susan, A. Caraba, A. Pacurari, G. Savoiu, I. Romosan
(Timisoara, Romania)

pS1-2 Arterial elasticity - Carotid artery e-tracking versus arteriograph method on brachial artery
Z. Miovski, L. J. Banfic, M. Vrkic Kirhmajer (Zagreb, Croatia)

pS1-3 Endothelial function in healthy individuals and patients with coronary artery disease
L. J. Banfic, Z. Miovski, K. Putarek, M. Vrkic Kirhmajer, M. Strozzi (Zagreb, Croatia)

pS1-4 Risk profile of cardiovascular diseases and subclinical atherosclerosis in HIV positive Polish patients
W. Kwiatkowska, B. Knysz, M. Czarnecki, J. Gasiorowski, J. Drelichowska-Durawa, M. Bubala,
J. Kwiatkowski, W. Witkiewicz, A. Gladysh (Wroclaw, Poland)

pS1-5 Endothelial prothrombotic markers in dyslipidemic patients
D. Karasek, H. Vaverkova, M. Halenka, Z. Frysak, D. Jackuliakova, D. Novotny, L. Slavik (Olomouc,
Czech Republic)

pS1-6 Soluble intercellular cell adhesion molecule-1 and vascular cell adhesion molecule-1 in asymptomatic
dyslipidemic subjects
D. Karasek, H. Vaverkova, M. Halenka, Z. Frysak, D. Jackuliakova, D. Novotny, J. Lukes (Olomouc,
Czech Republic)

pS1-7 Hypertension in patients with systemic lupus erythematosus (SLE)
M. Boucelma, H. Chaudet, A. Berrah (Algiers, Algeria - Marseille, France)

pS1-8 Impact of white matter changes on activities of daily living in mild to moderate dementia
S. Moon, D. L. Na (Suwon, Seoul, South Korea)

pS1-9 Simultaneous evaluation of coronary artery disease and aortic atherosclerosis using multidetector
CT in acute ischemic stroke patients
H. Kim, H. Cho, J. Lee, Y. Kim (Seoul, South Korea)

pS1-10 Stroke in the young: relation with thrombocytemia
M. Boucelma, S. Lassouaoui, D. Zemmour, H. Boudjelida, N. Ouadahi, A. Berrah (Algiers, Algeria)

14:00 - 15:30 pS2 - peripheral arterial disease (1) Room 8

pS2-1 Has MRA replaced conventional angiogram in the investigation of peripheral vascular disease?
A district general hospitals perspective
T. Hall, J. V. Barandiaran, N. El-Barghouti, E .P. Perry (Scarborough, UK)

pS2-2 Arteriomegaly in female subjects
T. Hall, J. V. Barandiaran, N. El-Barghouti, E. P. Perry (Scarborough, UK)

pS2-3 Different behaviour of pulse wave velocity and augmentation index in patients with peripheral arterial
disease
G. Scandale, G. Dimitrov, G. Carzaniga, M. Minola, M. Cinquini, M. Carotta, M. Catalano (Milan, Italy)

pS2-4 Increased aortic augmentation index in peripheral arterial disease
G. Scandale, A. Aceranti, G. Carzaniga, M. Minola, M. Cinquini, M. Carotta, M. Catalano (Milan, Italy)

pS2-5 Metabolic drugs increase effectiveness of medical treatment in smokers with intermittent claudication
M. S. Bogomolov, V. M. Sedov, G. Y. Sokurenko, L. N. Edovina, V. V. Slobodyanyuk (Saint-Petersburg,
Russia)

pS2-6 Influence of metabolic drugs on periferal hemodynamics of the legs in patients with intermittent
claudication
L. Edovina, M. Bogomolov, Y. Lukyanov, V. Slobodyanyuk (St-Petersburg, Russia)

pS2-7 Intima-media thickness increase and atherosclerotic plaques in asymptomatic patients
M. Cazaubon, F. A. Allaer (Paris, Dijon France)

pS2-8 Self-reported maximal walking capacity in arterial claudication: can the walking impairment
questionnaire be self-completed?
P. Abraham, N. Ouedraogo, G. Mahe, M. Vasseur, G. Leftheriotis (Angers, France)

pS2-9 Relationship of symptoms with non-ABI hemodynamic investigations on treadmill in patients with
suspected claudication
P. Abraham, G. Mahe, N. Ouedraogo, G. Leftheriotis, M. Vasseur (Angers, France)

pS2-10 Variability and short-term determinants of walking capacity in patients with intermittent claudication
P. Abraham, A. Le Faucheur, B. Noury-Desvaux, G. Mahe, T. Sauvaget, J. L. Saumet, G. Leftheriotis
(Angers, Les Ponts de Cé, Lyon, France)

14:00 - 15:30 pS3 - peripheral arterial disease (2) Room 8

pS3-1 Mortality and amputation rate of the conservative pharmacological treatment in patients with
critical leg ischemia unsuitable for revascularisation
R. Martini, R. Cordova, G. M. Andreozzi (Padova, Italy)

pS3-2 CRP levels as a predictor of restenosis following SFA revascularisation
P. Vale, S. Dubenec, D. Catinella, S. Hanning, A. Kelly (Sydney, Australia)

pS3-3 Plasma homocysteine level predictive of potential for restenosis after SFA revascularisation for
occlusive femoropopliteal disease
P. Vale, S. Dubenec, D. Catinella, S. Hanning, A. Kelly (Sydney, Australia)

pS3-4 Sternal wound angiogenesis in diabetic and non diabetic patients undergoing cardiac valve replacement
surgery
P. Bhaskaran, N. J. Standfield, T. Gourlay (London, Glasgow, UK)
10 ~

pS3-5 Assessment of sternal wound healing following diabetic and non diabetic coronary artery
bypass graft surgical patients using laser doppler imager
P. Bhaskaran, N. J. Standfield, T. Gourlay (London, Glasgow, UK)

pS3-6 Clinical significance of laser doppler scanner in peripheral vascular disease
P. Bhaskaran, M. Aslam, N. J. Standfield, T. Gourlay (London, Glasgow, UK)

pS3-7 Critical limb ischaemia in diabetes: definition, assessment, prognosis
F. Pollice, P. Pollice, V. Delgado (Leiden, Netherlands Antilles)

pS3-8 Association between microalbuminuria and elevated levels of proinflammatory endothelium-
derived mediators in hypertensive diabetic patients
C. Serban, S. Dragan, I. Mozos, R. Mateescu, L. Susan, A. Pacurari, A. Caraba, G. Savoiu, I. Romosan
(Timisoara, Romania)

pS3-9 Susceptibility of bacterial cultures to topical antiseptics in diabetic foot
L. Maslowski, M. Bartoszewicz, K. Checka, W. Kwiatkowska, W. Witkiewicz (Wroclaw, Poland)

pS3-10 Improving limb salvage in critical limb ischemia with intermittent pnuematic compression: a
controlled study with eighteen months follow up
S. Kavros, N. Turner, A. Voll, D. Liedl, P. Gloviczki (Rochester, USA)

14:00 - 15:30 pS4 - Vascular Surgery (1) Room 8

pS4-1 Comparison of endoluminal versus open repair in the treatment of abdominal aortic aneurysms
F. Pollice, P. Pollice, R. Rossi, G. Contegiacomo (Naples, Bari, Italy)

pS4-2 Endovascular thoracic aortic aneurysm repair in a patient with severe aortoiliac disease and ectopic single
kidney
M. Kafeza, V. Psarros, K. Papoutsis, G. Kouvelos, A. Koutsoubelis, C. Bakoyiannis, S. Georgopoulos,
C. Klonaris, E. Papalambros (Athens, Greece)

pS4-3 Late secondary procedures due to aneurysm rupture after EVAR: ten years experience
M. Kafeza, V. Psarros, A. Koutsoubelis, G. Kouvelos, K. Papoutsis, C. Bakoyiannis, C. Klonaris,
S. Georgopoulos, E. Bastounis, E. Papalambros (Athens, Greece)

pS4-4 Tissue factor pathway and thrombin-antithrombin complex in blood of patients with abdominal
aortic aneurysm during stent-graft implantation
R. Grendziak (Wroclaw, Poland)

pS4-5 A novel suture-less device (BYFix) for vascular anastomosis - the results of preclinical and clinical studies
B. Yoffe (Haifa, Israel - Klinik, Erfurt Germany)

pS4-6 Spontaneous aortocaval fistula: case report and literature review
H. Ravari, M. Moini, M. Vahedian, M. Aliakbarian (Mashhad, Tehran, Iran)

pS4-7 The role of arterial and venous shunting in the complex vascular trauma of the arteries of the lower
limbs
G. Marcucci, A. Siani, R. Antonelli, A. G. Giordano, F. Accrocca (Civitavecchia, Rome, Italy)

pS4-8 The percutaneous angioplasty and stenting treatment in patients with subclavian steal syndrome
F. Ferrara, I. Muratori, F. Meli, C. Amato, M. Lunetta, R. Alcamo, S. Novo (Palermo, Italy)

pS4-9 Diagnostic procedures: the timing of follow-up of surgical and endovascular treatment of arterial diseases
P. L. Antignani, C. Allegra (Rome, Italy)


pS4-10 Below the knee bypass using cryopreserved arterial homografts for critical lower limb ischaemia:
long term results in a single center
S. Amiot, C. Perot, R. Spear, R. Jashari, D. Massouille, J. Lancelevee, J. P. Chambon (Lille, France -
Brussels, Belgium)

14:00 - 15:30 pS5 - Vascular Surgery (2) Room 8

pS5-1 Intraoperative aortic embolism after middle lobe lobectomy for renal leyomiosarcoma metastases
P. Amorim, C. Rodrigues, A. Rita Matos, T. Vieira, F. Félix, J. Pereira Albino (Lisbon, Portugal)

pS5-2 Endoluminal stenting for superficial femoral artery occlusion offers symptomatic improvement
for patients with peripheral vascular disease
J. Makanjuola, V. M. Patel, M. Mobasheri, T. Hussain (London, UK)

pS5-3 Endoluminal revascularization of non embolic iliac occlusion for inferior limb acute ischemia:
an alternative to surgery
F. Mercier, A. Aymard, H. Benamer, X. Guillotte, E. Louvard, R. Maguemoun, M. C. Morice
(Aubervilliers, France)

pS5-4 Carotid angioplasty. Detection of embolic signals during and after the procedure

pS5-5 Influence of age upon complication of carotid artery stenting

pS5-6 Internal carotid and bilateral vertebral arteries dissection: a case report
M. Boucelma, T. Bounzira, D. Bensalah, D. Hakem, A. Berrah (Algiers, Algeria)

pS5-7 Surgery for carotid body tumor in patient with Eisenmenger syndrome (case report)
K. Kanalikova, J. Tomka, K. Kanalikova, I. Simkova, Z. Zita, L. Pretiova (Bratislava, Slovak Republic)

pS5-8 A rare carotid-jugular fistula of congenital etiology
J. Pereira Albino, P. Amorim, L. Castro E Sousa, K. Ribeiro, G. Sobrinho, T. Vieira, N. Meireles,
F. Pinto (Lisbon, Portugal)

pS5-9 Diagnosing carotid-jugular arteriovenous fistula: is color doppler sonography enough?
R. Catalini, G. Pagliariccio, L. Giantomassi, O. Zingaretti (Ancona, Italy)

pS5-10 Ruptured iliac artery aneurysm after abdominal aortic aneurysm resection: a case report
T. Janusauskas, E. Janusauskas, V. Kazlauskas, D. Triponiene, V. Triponis (Vilnius, Lithuania)



therapeutic education of the vascular patient
Chairpersons: P. Carpentier (Grenoble, France), P. Léger (Toulouse, France)

Sy5-1 s Therapeutic education of the patient with peripheral arterial disease

Sy5-2 Education of the patient with venous thromboembolic disease
s
P. Léger (Toulouse, France)

Sy5-3 s Therapeutic education of the patients with chronic venous disorders
B. Satger (La Léchère, France)

12 ~

16:00 - 17:30 OC3 - Free Oral Communications - Venous thromboembolic disease Petit Amphithéâtre

Chairpersons: G. Pernod (Grenoble, France), A. Visona (Castelfranco Veneto, Italy)

OC3-1 Comparison of the clinical history of symptomatic isolated muscular calf vein thrombosis
versus deep calf vein thrombosis
J. Galanaud, M.A. Sevestre, C. Genty, J.P. Laroche, V. Zyzka, I. Quere, J.L. Bosson (Montpellier, Amiens,
Grenoble, Fort de France, France)

OC3-2 Bleeding complications in patients with cancer receiving anticoagulant therapy for venous
thromboembolism. findings from the RIETE registry
A. Visonà, P. Di Micco, J.A. Nieto, J. Truijllo Santos, R. Quintavalla, P. Prandoni, M. Monreal
(Castelfranco Veneto, Naples, Parma, Padua, Italy - Cuenca, Cartagena, Badalona, Spain)

OC3-3 Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism. Findings
from the RIETE registry
A. Visonà, P. Di Micco, A. Niglio, M. Amitrano, M. Ciammaichella, P. Prandoni, M. Monreal,
J.A. Nieto (Castelfranco Veneto, Naples, Avellino, Rome, Padua, Italy - Badalona, Cuenca, Spain)

OC3-4 Venous thromboembolism in the elderly: epidemiological data overview based on the prospective
OPTIMEV cohort
G. Pernod, M. A. Sevestre, C. Genty, J. Labarere, P. Couturier, J. L. Bosson (Grenoble, Amiens, France)

OC3-5 Thrombosis of atypical location, Mayo series: profile of local causes in organ vein thrombosis
W. Wysokinski, R. Mcbane (Rochester, USA)

OC3-6 Evaluation of a pneumatic device efficacy to prevent venous disorders in air travel
F. Fernandez, I. Chirosa, M. Martinez, J.J. Sánchez-Cruz, E. Ros (Granada, Spain)

OC3-7 Calf vein thrombosis and risk of pulmonary embolism
P. L. Antignani, C. Allegra (Rome, Italy)

17:30 - 18:30 SY6 - Corporate Symposium Cook Medical Amphitheatre Lavoisier

New developments in endovascular technologies
Chair: N. Chakfé (Strasbourg, France)

Sy6-1 s Fenestrated endografts for thoracoabdominal aortic pathologies
J-P. Becquemin (Créteil, France)

Sy6-2 s Future developments in Abdominal Aortic Aneurysm treatment
F. Thaveau (Strasbourg, France)

Sy6-3 s there a room for drug eluting stents in SFA lesions?
Is
N. Chakfé (Strasbourg, France)

17:30 - 18:30 SY7 - Symposium Petit Amphithéâtre

New insights about the calf muscle pump function
Chairpersons: P. Carpentier (Grenoble, France), A. Nicolaïdes (Nicosia, Cyprus)
Organized thanks to an unrestricted educational grant from Ad Rem Technology - VEINOPLUS

Sy7-1 Pathophysiology of the calf muscle pump
s
A. Nicolaïdes (Nicosia, Cyprus)

Sy7-2 Functional anatomy of the muscular pumps of the lower limb
s
J.F. Uhl (Paris, France)

s to improve the calf muscle function in CVD patients
How
A. Jawien (Bydgoszcz, Poland)


Scientific Program - Saturday, September 25, 2010

08:30 - 09:20 Plenary lecture Amphitheatre Lavoisier

Chair: A. Jawien (Bydgoszcz, Poland)

the 2010 milestones of the vascular physician
J. Belch (Dundee, UK)


Venous thromboembolic disease: moving Concepts and practices
Chairpersons: I. Quéré (Montpellier, France), A. Comerota (Michigan, USA)
Organized thanks to an unrestricted grant from Eumedica

Sy8-1 s Medical signification of the asymptomatic venous and pulmonary embolism
G. Pernod (Grenoble, France)

Sy8-2 s Newer trends in the management of thrombosis. Impacts on Vascular Indications
E. Kalodiki (London, UK)

Sy8-3 s Superficial thrombophlebitis, a significant subset of venous thromboembolic disease
I. Quéré (Montpellier, France)

Sy8-4 s The concept of early thrombus removal for iliofemoral deep venous thrombosis
A. Comerota (Michigan, USA)

09:30 - 11:00 Postgraduate Course Petit Amphithéâtre

Leg and foot ulcers - Critical limb ischemia
Moderators: P. Carpentier (Grenoble, France), M.-A. Sevestre-Pietri (Amiens, France)
Experts: K. Roztocil (Prague, Czech Republic), G. Marcucci (Rome, Italy), M.C. Portilho (Brazil),
P. Gloviczki (Rochester, USA)

This session is based on the interactivity between the audience and an international panel of experts
discussing decision making about clinical cases with the help of concordance script tests and the powervote
technique.
At the end of the session, participants will understand the importance of a thorough medical diagnostic
and pre-therapeutic evaluation of patients with leg or foot ulcers; they will have an increased awareness
of the educational and social needs of these patients; they will be able to make the diagnosis of critical
limb ischemia and will understand the need for a multidisciplinary approach of the patient suffering
from this condition.



Varicose vein treatment in the future
Chairpersons: M. de Castro-Silva (Belo Horizonte, Brazil), P. Nicolini (Lyon, France)

Sy9-1 s Clinical Practice Guidelines of the Society for Vascular Surgery and the American Venous Forum on
3 the Care of Patients with Varicose Veins
P. Gloviczki (Rochester, USA)

Sy9-2 s Future techniques for varicose vein ablation
P. Nicolini (Lyon, France)

14 ~

Sy9-3 s We need to know more about the natural history of venous hemodynamics in patients with varicose veins!
O. Pichot, P. Carpentier (Grenoble, France)

Sy9-4 s Molecular Mechanisms for Microvascular Endothelial Apoptosis under Pressure Elevation and
Therapeutic Targets
G. Schmid-Schönbein (San Diego, USA)


Venous thromboembolic disease - thrombophilia
Moderators: G. Pernod (Grenoble, France), P. Nguyen (Reims, France)
Experts: A. Visona (Castelfranco Veneto, Italy), M.E. Renno de Castro Santos (Brazil),
M. Sprynger (Liège, Belgium)

discussing decision making about clinical cases with the help of concordance script tests and the
powervote technique.
At the conclusion of the session, attendees will have an increased awareness of the importance of
the evaluation of the benefit/risk ratio for the decision about the treatment of these conditions. They
will have a deeper understanding of the clinical signification of the different inherited and acquired
thrombophilia and the drawbacks of their systematic evaluation.

13:00 - 14:00 Break - Posters and Exhibition visit Room 8


Ultrasound guided procedures
Chairpersons: O. Pichot (Grenoble, France), E. Ascher (New York, USA)

Sy10-1 Ultrasound assisted arterial procedures
s
E. Ascher (New York, USA)

Sy10-2 Vascular access for hemodialysis
s
O. Pichot (Grenoble, France)

Sy10-3 Ultrasound guided treatment of varicose veins
s
C. Hamel-Desnos (Caen, France)


Clinical microcirculation
Moderators: M. Vayssairat (Paris, France), P. Carpentier (Grenoble, France)
Experts: C. Allegra (Rome, Italy), A.T. Guillaumon (Brazil), J.C. Wautrecht (Brussels, Belgium)

discussing decision making about clinical cases with the help of concordance script tests and the
powervote technique.
At the end of the session, participants will have a broader understanding of the needs of patients
seeking medical help for a vascular acrosyndromes, and will be able to diagnose atypical
acrosyndromes such as complicated chilblains and paroxystic finger hematoma and to manage a cost
effective etiological evaluation of Raynaud phenomenon.

14:00 - 15:30 Posters Sessions - PS6 to PS9 Room 8

Presenting authors are requested to stand close to their poster during the guided visit. Authors will have
4 minutes to present orally their work.


14:00 - 15:30 pS6 - arteritis, vasculitis, therapeutic Room 8

pS6-1 Generic argatroban preparations differ in their anticoagulant and antiprotease responses in
patients with liver disease. Dosing implications
D. Hoppensteadt, O. Iqbal, S. Masood, J. Fareed (Maywood, USA)

pS6-2 Prevalence of free methyl chloride as an impurity in generic clopidogrel preparations. Safety implications
in cardiovascular patients
A. Duguot, H. Belva-Besnet, C. Conocar, M. Daumas, G. Rao, I. Mohan Theti (Paris, France - Bangelore,
India)

pS6-3 Low adherence to antithrombotic indications and gender differences in aspirin use in patients
with previous minor bleeding
A. Mattioli, A. Farinetti, R. Lonardi, S. Pennella, G. Tazzioli, G. Mattioli (Modena, Italy)

pS6-4 The pharmacogenetic approach to the anticoagulant therapy
Y. Novikova, A. Shevela, G. Lifshitz, K. Sevostyanova, E. Voronina (Novosibirsk, Russia)

pS6-5 Multifactorial treatment effectivness of dyslipidemia, type 2 diabetes mellitus and arterial hypertension
in patients with CHD
K. Kapanadze, N. N. Kipshidze (Tbilsi, Georgia)

pS6-6 Hyperbaric oxygen therapy in refractory ischemic cutaneous lesions in vasculitis and connective
vascular disease
C. Belizna, D. Henrion, V. Soude, B. Bienvenu, F. Maillot, E. Andres, C. Lavigne, A. Ghali, A. Mercat,
P. Asfar (Angers, Caen, Tours, Strasbourg, France)

pS6-7 Digital ischemia and myeloproliferative disorders
B. Imbert, N. Kherat, I. Marie, H. Desmurs-Clavel, P. Carpentier (Grenoble, Rouen, Lyon, France)

pS6-8 Prophylaxis of suspected secondary Raynaud’s phenomenon
C. Costa Almeida, L. Carvalho, L. Reis, J. Fortuna, C. Costa Almeida (Coimbra, Portugal)

pS6-9 Abdominal aortitis and doxycyclin: case report
M. Sprynger, C. Nizet, L. A. Pierard (Liege, Belgium)

pS6-10 Treatment of non-healing wounds with autologous bone marrow cells, platelets, fibrin glue, and collagen
matrix
H. Ravari, D. Hamidi Almadrai, M. Salimifar, S. H. Bonakdaran (Mashhad, Iran)

pS6-11 Association of heparin-PF4 antibodies with intima-media thickness of carotid arteries
A. Mattioli, A. Farinetti, R. Lonardi, S. Pennella, G. Mattioli (Modena, Italy)

pS6-12 A collaborative multi-disciplinary community approach to a streptococcus pyogenes infection
G. Hancock, J. V. Barandiaran, T. C. Hall, N. El-Barghouti, E. P. Perry (Scarborough, UK)

14:00 - 15:30 pS7 - Chronic venous disorders / Lymphedema Room 8

pS7-1 Are there incurable leg ulcers?
F. Zernovicky, K. Samelova, F. Zernovicky Jr. (Bratislava, Slovak Republic)

pS7-2 Phlebological passport
T. Alekperova, A. Truxanov, S. Musaeva, O. Alekperov (Moscow, Russia)

pS7-3 Electro-stimulation with VEINOPLUS® - a new method for the treatment of chronic venous insufficiency
of the lower limbs
V. Y. Bogachev, O. V. Golovanova, A. H. Kuznietov, A. O. Stchekoian (Moscow, Russia)
16 ~

pS7-4 Observational study of the synergy between sclerotherapy and a grade a veinotonic in chronic venous
disease of the lower limbs
F. Allaert, J. P. Gobin (Dijon, Lyon, France)

pS7-5 Leg ulcers and hydroxyurea: has the treatment to be discontinued?
U. Michon-Pasturel, I. Lazareth, A. Bouchareb, P. Priollet (Paris, France)

pS7-6 Predictors of the post-thrombotic syndrome during long-term treatment of proximal deep vein
thrombosis
F. Pollice, P. Pollice, B. Di Renzo (L’Aquila, Italy)

pS7-7 Treatment of low-flow vascular malformations by echo-sclerotherapy with polidocanol foam:
24 cases and literature review
S. Blaise, M. Charavin-Cocuzza, H. Riom, M. Brix, C. Seinturier, J. M. Diamant, G. Gachet,
P. H. Carpentier (Grenoble, Voiron, France)

pS7-8 Intensive rehabilitation program for lymphedema: one or two weeks?
B. Villemur, F. Vellut, J. Y. Bouchet, B. Bucci, V. Evra, M. P. De Angelis, A. Marquer, D. Perennou
(Echirolles, France)

pS7-9 Prognostic value of lymphoscintigraphy for prediction of postmastectomy lymphedema
M. Myasnikova, N. Gordeev (St-Petersburg, Russia)

pS7-10 Effectiveness of multilayer bandage in healing venous ulcers
F. Ferrara, I. Muratori, F. Meli, C. Amato, M. Lunetta, R. Alcamo, S. Novo (Palermo, Italy)

14:00 - 15:30 pS8 - Varicose veins Room 8

pS8-1 Vein - Term classification/ venous reflux patterns and great saphenous vein sparing
F. Toscano, C. Pereira Alves, J. Neves, A. Formiga (Lisbon, Portugal)

pS8-2 Clinical experience of Salem endothelial stripping operation for the surgical treatment of primary
varicose veins of the lower limbs
M. Salem, A. Salem, T. Salem (Alexandria, Egypt)

pS8-3 Early results from sclerotherapy for treatment of varicose veins
D. Lukanova, I. Lozev (Sofia, Bulgaria)

pS8-4 Preoperative and intraoperative triplex sonography in surgical treatment of varicose veins
I. Lozev, N. Smilov, P. Lozev, D. Dardanov, G. Kirov (Sofia, Bulgaria)

pS8-5 Treatment of symptomatic varicose veins and small saphenous vein reflux with endovenous laser
ablation does not require concomitant phlebectomy
J. Laredo, J. Kwock, B. B. Lee, R. F. Neville (Washington, USA)

pS8-6 Endovenous laser ablation of the anterior accessory great saphenous vein
J. Laredo, S. Shin, B. B. Lee, R. F. Neville (Washington, USA)

pS8-7 A pilot randomised trial of catheter directed foam sclerotherapy with tumescence versus laser ablation in
patients with large saphenous diameters: A N
C. R. Lattimer, E. Shawish, E. Kalodiki, M. Azzam, G. Geroulakos (London, UK)

pS8-8 Personal experience in preserving the great saphenous vein
I. Bihari (Budapest, Hungary)

pS8-9 Incompetent perforators - the unseen villain
C. Stuckey, C. Barbieri, A. Martin, K. Mcdonald, C. Conroy, R. Martin, D. Rollins (Overland Park, USA)


PS8-10 Endovenous laser ablation in treatment of varicose veins
M. Vakhitov, D. Semenov, A. Zsibin, Z. Ulimbasheva (St. Petersburg, Russia)

PS8-11 Endovascular and surgical threatment of pelvic congestion syndrome
I. Ignatyev, R. Bredikhin, E. Fomina, M. Miikhailov (Kazan, Russia)

14:00 - 15:30 PS9 - Venous thromboembolic disease Room 8

PS9-1 Venous diseases in injecting drug users
M. Czarnecki, B. Knysz, W. Kwiatkowska, J. Gasiorowski, A. Gladysz (Wroclaw, Poland)

PS9-2 Evaluation of outcomes following endovascular recanalization and stenting of chronically occluded
iliac and common femoral veins
A. Kurklinsky, H. Bjarnason (Rochester, USA)

PS9-3 Importance of long term follow up of dVt recanalisation
Z. Pécsvárady (Kistarcsa, Hungary)

PS9-4 the genetic predicts of the deep venous thrombosis
Y. Novikova, A. Shevela, K. Sevostyanova, E. Voronina (Novosibirsk, Russia)

PS9-5 Clinical signs and risk factors of deep veins thrombosis of lower extremities. efficiency and safety of
anticoagulant therapy
V. Mishalov, E. N. Amosova, N.Y. Litvinova (Kyiv, Ukraine)

PS9-6 Prevention of thrombotic disorders in cancer patients undergoing chemotherapy
F. Pollice, P. Pollice, L. De Giuli (L’Aquila, Italy)

PS9-7 Validation of a deep vein thrombosis prediction rule in primary care
M. Maufus, J. L. Bosson, C. Genty, A. Delluc, P. Imbert, P. Gagne, C. Rolland, L. Bressollette,
G. Le Gal (Brest, Grenoble, Plaintel, France)

PS9-8 deep vein thrombosis in intravenous drug users from experience of angiologic ward and outclinic
W. Kwiatkowska, D. Kotschy, J. Przytulska, J. Drelichowska-Durawa, L. Maslowski, W. Witkiewicz,
M. Czarnecki, J. Gasiorowski, B. Knysz (Wroclaw, Poland)

PS9-9 Factors influencing the development of the post-thrombotic limb

PS9-10 Ivus IVc filter deployment - a method for integration of IVus into daily practice
D. Kassavin, G. Constantinopoulos (Long Branch, NJ, USA)

15:00 - 15:30 coffee break - Posters and Exhibition visit Room 8

15:30 - 17:30 Plenary session Amphitheatre Lavoisier

Forum of Vascular Initiatives
chairpersons: R. simkin (Buenos Aires, Argentina), P. carpentier (Grenoble, France)

s Vascular centers
F. Benedetti-Valentini (Rome, Italy)

s the adventure of running a vascular journal
A. Nicolaïdes (Nicosia, Cyprus)

s Building-up an e-learning vascular website
P. Carpentier (Grenoble, France), C. Boissier (Saint-Etienne, France)

18 ~

s VAS (Vascular - Independent Research and Education - European Organisation): almost 20 years of
stable European collaboration on Angiology/Vascular Medicine
M. Catalano (Milan, Italy)

s Brazilian experience on vascular teaching
J.L. Nascimento Silva (Rio De Janeiro, Brazil)

s Franco-Vietnamese vascular teaching cooperation
P. Desouter, J.M. Diamand (Grenoble, France)

s The Italian Likoni project in Kenya
C. Allegra (Rome, Italy)

s Fighting elephantiasis in Burkina Faso
A. Cornu-Thénard (Paris, France)

s IUA Eurochap 2011 in Slovenia
P. Poredos (Ljubljana, Slovenia)

s IUA World Congress in Prague
K. Roztocil (Prague, Czech Republic)


Scientific Program - Sunday, September 26, 2010

09:30 - 11:00 SY11 - Joint Symposium with the Italian Society of Angiology
Petit Amphitheatre
and Vascular Medicine
physical exercise and Vascular medicine
Chairpersons: P.L. Antignani (Rome, Italy), G.M. Andreozzi (Padova, Italy), P. Abraham (Angers, France)

Sy11-1 s Effects of physical exercise on the cardiovascular system
P. Abraham (Angers, France)

Sy11-2 s The balance or unbalance of ATS risk factors could compromise the results of physical training in
claudicants ?
G.M. Andreozzi (Padova, Italy)

Sy11-3 s Interval training in patients with intermittent arterial claudication
B. Villemur (Grenoble, France), D. Pérennou (Grenoble, France)

Sy11-4 s Physical training in patients with hypertension
A. Pinto (Palermo, Italy)

Sy11-5 s Physical exercise in elderly arteriopathic patients
M. Prior (Verona, Italy)

09:30 - 11:00 OC4 - Free Oral Communications - Varicose veins Room 262

Chairpersons: E. Kalodiki (London, UK), C. Allegra (Roma, Italy)

OC4-1 Anatomic preconditions for recurrent varices in surgical treatment of primery varicose veins
M. Vakhitov, O. Bolshakov, V. Amosov, O. Kovaleva (St. Petersburg, Russia)

OC4-2 Closurefast catheter endovenous ablation - a three year experience
C. Stuckey, C. Barbieri, A. Martin, K. Mcdonald, C. Conroy, R. Martin, D. Rollins (Overland Park, USA)

OC4-3 Treatment of superficial venous insufficiency by endovenous laser therapy: lessons from a personal trial
on 1000 cases
P. Sarradon, E. Slotema (Toulon, Marseille, France)

OC4-4 Endovenous radiofrequency-powered segmental thermal ablation (RSTA) of the great saphenous vein:
2-year european follow-up
O. Pichot (Grenoble, France)

OC4-5 Clinical comparison of thigh only versus endovenous laser ablation (EVLA) in great saphenous vein
insufficiency treatment
R. Kikuchi, E. Arcenio, C.M. Oba (Sao Paulo, Londrina, Brazil)

OC4-6 A seven fold increase in volume flow in the great saphenous vein during application of a below knee
stocking: a potential hazard following foam sclero
M. Azzam, C. R. Lattimer, E. Kalodiki, G. Geroulakos (London, UK)

OC4-7 The role of foam sclerotherapy in elderly patient (over 70) with severe disabling CVD
C. Allegra, P. L. Antignani, M. Gallucci (Rome, Italy)

11:00 - 11:30 Coffee break - Exhibition visit Room 8

20 ~


From raynaud phenomenon to digital ulcer
Chairpersons: M. Cutolo (Genova, Italy), M. Vayssairat (Paris, France)
Organized thanks to an unrestricted educational grant from Actelion Pharmaceuticals

Sy12-1 s Basic exploration of Raynaud’s phenomenon : a consensus of French experts
J. Constans (Bordeaux, France)

Sy12-2 s Clinical usefulness of capillaroscopy
M. Cutolo (Genova, Italy)

Sy12-3 s Raynaud phenomenon: the appearance of digital ulcers changes everything

Sy12-4 s The therapeutic challenge of digital ulcers in systemic sclerosis
P. Priollet (Paris, France)

11:30 - 13:00 OC5 - Free Oral Communications - atherosclerosis Room 262

Chairpersons: C. Le Hello (Caen, France), M. Cazaubon (Paris, France)

OC5-1 Easy assessment of dietary pattern for atherosclerosis diseases in clinical practice
G. Mahe, M. Carsin, J. P. De Bosschere, M. Zeeny (Angers, Rennes, France - Beirut, Lebanon)

OC5-2 Medical management and prognosis of patients with atherothrombotic disease requiring a revas-
cularisation
C. Le Hello, R. Morello, S. Fradin, O. Coffin, D. Maïza, M. Hamon (Caen, France)

OC5-3 Management of vessel wall disease is better than the management of risk factors
G. H. R. Rao, V. Sriram, G. Muralidhara, A. Fenster (Minnesota, USA - Ontario, Canada)

OC5-4 Computed tomographic angiography for the evaluation of carotid artery stenosis

OC5-5 Percutaneous treatment with drug-eluting stent in diabetic patients
F. Pollice, P. Pollice, T. Grover, I. Christensen (Leiden, Netherlands Antilles)

OC5-6 Low ankle brachial index is a risk factor for revascularization in coronary patients
M. Maufus, J. B. Guitton, G. Vanzetto, L. Belle, B. Imbert, P. Carpentier, G. Pernod (Grenoble, Annecy,
France)

OC5-7 Progression of peripheral arterial disease in type 2 diabetic patients: influence of fibrinogen and crp
M. Bosevski, L. J. Georgievska-Ismail (Skopje, Makedonija)

13:00 - 14:00 Break - Exhibition visit Room 8


Critical Limb ischemia
Chairpersons: K. Roztocil (Prague, Czech Republic), E. Emmerich (Paris, France)
Organized thanks to an unrestricted grant from Sanofi Aventis

Sy13-1 s A randomized, double-blind, placebo-controlled gene therapy study using NV1FGF for prevention of
amputation and death in critical limb ischemia (TAMARIS). Rationale, design and baseline patient
characteristics
J. Belch (Dundee, UK)


Sy13-2 s Pathophysiology of Critical Limb Ischemia

Sy13-3 s Critical Limb Ischemia: the Limits of Revascularization
E. Ascher (New York, USA)

s Results of gene and cell therapy in CLI: are we close to salamander?
J. Emmerich (Paris, France)

14:00 - 15:30 SY14 - Joint Symposium with the Romanian Society of Angiology and
Petit Amphitheatre
Vascular Surgery
Complications of vascular procedures
Chairpersons: A. Andercou (Cluj-Napoca, Romania), D. Olinic (Cluj-Napoca, Romania)

Sy14-1 s Anastomotic aneurysms and infections after peripheral procedures
A. Andercou, O. Andercou, B. Stancu, O.Budiu, O. Barbos, M. Andrei (Cluj-Napoca, Romania)

Sy14-2 s Complications after interventional venous procedures
M. Catalano, E. Perilli (Milan, Italy)

Sy14-3 s Complications of vascular access
I. Droc, V. Alexandrescu (Bucharest, Romania)

Sy14-4 s Early failure of arteriovenous fistula for hemodialysis
V. Popovic, J. Pasternak, J. Pfau, M. Kacanski, D. Nikolic, Z. Horvat (Novi Sad, Serbia)

Sy14-5 s Interventional retrieval of fractured central venous catheter
D. Olinic, C. Homorodean, M. Olinic, M. Ober (Cluj-Napoca, Romania)

14:00 - 15:30 OC6 - Free Oral communications
Room 262
rare vascular diseases and progress in vascular diagnosis
Chairpersons: G. Gerotziafas (Paris, France), M.L. Gloviczki (Rochester, USA)
OC6-1 A new diagnostic criterion with colour duplex scanning in pudendal neuralgia by entrapment
M. Mollo, E. Bautrant, J. Eggermont, A. K. Rossi-Seignert (Aix-en-Provence, France)

OC6-2 Long term follow-up of giant cell arteritis-related upper/lower limb vasculitis. a series of 36 patients
C. Assie, A. Janvresse, D. Plissonnier, H. Levesque, I. Marie (Rouen, France)

OC6-3 Digestive arteries dissection in a retrospective monocentric series
C. Belizna, A. Ghali, C. Lavigne, A. Beucher, F. Thouveny, S. Willoteaux, J. Piquet, B. Enon (Angers,
France)

OC6-4 Evaluation of thrombin generation assay in the monitoring of treatment with vitamin K antagonists,
enoxaparin and fondaparinux
G. Gerotziafas, V. Galea, M. Chaari, M. Sassi, H. Baccouche, I. Elalamy (Paris, France)

OC6-5 Application of 3 tesla blood oxygen level dependent (BOLD) magnetic resonance imaging
(MRI) to study oxygenation of the kidney in renovascular disease
M. L. Gloviczki, J. Glockner, J. P. Grande, L. O. Lerman, S. C. Textor (Rochester, USA)

OC6-6 Duplex guided angioplasty of arteriovenous fistulae for hemodialysis: retrospective study of 45 patients
in a French univeristary hospital
A. Dessi, C. Seinturier, O. Pichot, E. Cochet, P. H. Carpentier, C. Sessa (Grenoble, France)

OC6-7 Klippel-Trenaunay-Weber syndrome and epithelioid angiosarcoma. a rare association
J. Pereira Albino, A. Simas, C. Matos, G. Sobrinho, V. Brotas, N. Meireles, G. Clara (Lisbon, Portugal)

22 ~

15:30 - 16:00 Break - Exhibition visit Room 8

16:00 - 17:30 SY15 - Joint Symposium Eurochap - Microcirculation Amphitheatre Lavoisier

relationship between macro and microcirculation
Chairpersons: B. Levy (Paris, France), H.A.J. Struijker-Boudier (Maastricht, the Netherlands)

s The development of microvascular networks
F. Le Noble (Berlin, Germany)

Sy15-2 s Modulation of small artery flow: wall remodeling and perivascular adipose tissue
A. Greenstein (Manchester, United Kindom)

Sy15-3 s Relationship between macro- and microcirculation
P. Boutouyerie (Paris, France)

s Match and mismatch between large arteries and microcirculation
G. London (Paris, France)

16:00 - 17:30 OC7 - Free Oral communications - Venous disorders Room 262

Chairpersons: F. Allaert (Dijon, France), M. Jezovnik (Ljubljana, Slovenia)

OC7-1 Treatment of venous stasis ulcer, through cell therapy with keratinocyte autograft in patients users of
micronized diosmin and hesperidin
A. Guillaumon, C. Bosnardo, M. B. Puzzi, J. Rheder (Campinas, Brazil)

OC7-2 Assessing mesoglycan treatment efficacy in 1483 outpatients with chronic venous insufficiency
C. Allegra, P. L. Antignani (Rome, Italy)

OC7-3 Clinical and haemodynamic sequelae of deep venous thrombosis
F. Pollice, P. Pollice, M. Sansone (l’Aquila, Italy)

OC7-4 Post-surgical vein thrombosis and onset of post-thrombotic syndrome: influence of 4G/5G
polymorphism
F. Ferrara, C. Amato, F. Meli, I. Muratori, M. Lunetta, I. R. Alcamo, S. Novo (Palermo, Italy)

OC7-5 Anatomical description of the ostial valve in the saphenofemoral junction
C. Tasch, L. Larcher, E. Brenner (Schongau, Germany - Feldkirch, Innsbruck, Austria)

OC7-6 Meta-analysis approach of the effect of venoactive drug on ankle circum-ference in CVD patients
F. Allaert (Dijon, France)

OC7-7 Inflammation - pathogenetic mechanism of venous thrombosis
M. Jezovnik, P. Poredos (Ljubljana, Slovenia)


E
HIBITION PLAN

Stand Exhibitors

N° 1 KREUSSLER PHARMA
N° 2 AD REM TECHNOLOGY - VEINOPLUS
N° 3 LABORATOIRES INNOTHERA
N° 4 PIERRE FABRE
N° 5 MINERVA MEDICA
N° 6 SIGVARIS
N° 7 PERIMED

Stand Exhibitors

N° 1 KREUSSLER PHARMA
N° 2 AD REM TECHNOLOGY - VEINOPLUS
N° 3 LABORATOIRES INNOTHERA
N° 4 PIERRE FABRE
N° 5 MINERVA MEDICA
N° 6 SIGVARIS
N° 7 PERIMED
N° 8 DANISH MYO TECHNOLOGY A/S
N° 9 WILEY BLACKWELL
N° 10 ADINSTRUMENTS LTD
N° 11 IMMUNDIAGNOSTIK AG
N° 12 CELLIX LTD
N° 13 RHEO MEDITECH, INC
N° 14 MOOR INSTRUMENTS
N° 15 LIVING SYSTEMS INSTRUMENTATION


SympOSia at 178€ based upon all cause mortality. This is lower than 1/10 of the
costs in the well-known implemented cancer programs.
Sy 1 - abdominal aortic aneurysms: an update In all, offering men aged 65-74 years screening for AAA seems
acceptable according to criteria from Council of Europe, however
Sy1-1 patHOGeNeSiS OF abdOmiNaL aOrtiC nation-wide implementation in Europe is only ongoing in UK.
aNeUrySmS
E. ALLAIRE1 Sy1-3 tHe LONG-term reSULtS OF tHe eVar i
1 Department of Vascular Surgery, Henri Mondor Hospital, Créteil, triaL
France J. T. POWELL1
1 Vascular Surgery Research Group, Imperial College at Charing
Abdominal aortic aneurysms (AAAs) form and rupture because of Cross, St Dunstan’s Road, London W6 8RP, UK
the destruction of aortic extracellular matrix digested by an excess of
proteinases. Some of these proteinases are activated by the plasmin The 3 published randomised trials comparing elective endovascular
pathway. Inflammatory cells infiltrating the aortic wall are important versus open repair for abdominal aortic aneurysms have been
sources of proteinases. Other cells – endothelial, vascular smooth remarkably consistent in showing a 3-fold 30-day operative survival
muscle cells- are other putative sources. An important specificity of benefit of endovascular aneurysm repair (EVAR)1-3. These trials
AAAs is the disappearance of vascular smooth muscle cells (VSMCs) (EVAR-1, DREAM and OVER) also have reported mid-term results,
in the media layer, which may impair adequate wall repair. In addition, with survival rates to between 2 and 4 years after randomisation4;5.
VSMCs produce TGF-beta1 and inhibitors of proteinases, thereby However the long-term follow of the EVAR trials6;7 has yielded some
protecting the aortic wall against inflammation and proteolysis. Lack surprises.
of VSMCs may turn the aortic wall into a structure vulnerable to The EVAR 1 trial randomised patients with large aneurysms (at least 5.5
inflammation-driven proteolysis. cm in diameter, anatomically suitable for EVAR) to either endovascular
Recent data have linked the formation of a luminal thrombus and AAA repair or open repair. After 8 years of follow-up, 54% remained alive,
expansion. The surface of the thrombus promotes the recruitment of exactly the same proportion in those randomised to EVAR as in those
polymorphonuclears which deliver an excess of proteases to the wall. randomised to open repair: EVAR was not associated with a long-term
The atrophy of AAA wall is in fact more severe at sites of thrombus survival benefit6. Therefore, other long-term outcomes assume greater
accumulation. The exact mechanisms by which AAAs rupture remains importance to more than half of the patients, particularly the new
poorly documented. The accumulation of destructive factors is focal endograft-related complications reported throughout follow-up. The
at site of rupture, suggesting a very local phenomenon. Recent report reporting of new endograft-related complications was highest within
suggest that inflammation may not be the main feature of ruptured the first 6 months of aneurysm repair (22.9 new complications per 100-
areas, but rather excessive angiogenesis. patient years of follow up), reducing to 3.4 new complications per 100-
A last striking feature is that patients with AAAs associated to patient years of follow up between 6 months and 4 years, with weak
atherosclerosis have generalized “atrophy” of vessels distant to the evidence that rates might start to increase again after 4 years. There is
main lesion, and that other tissues of these patients heal poorly. Recent other evidence to indicate that EVAR might not be as durable as open
data from our laboratory suggest that mechanisms of healing of tissues repair. There were 25 secondary ruptures after EVAR, the majority
under strain are altered in these patients. This observation may help (72%) of which proved to be fatal. In contrast, there were no secondary
identify new molecular and genetic factors linked to this deadly aortic ruptures reported after open repair.
disease. The promotion of aortic healing represents an innovative These endograft ruptures appear to explain the erosion of the statistically
approach for future treatments alternative to interventional techniques. significant 3% aneurysm-related survival benefit for EVAR versus open
repair, observed during the first 4 years of follow up5.
Sy1-2 SCreeNiNG FOr abdOmiNaL aOrtiC These long-term results question the durability of EVAR and for the
aNeUrySmS moment there is no better evidence. Or is perhaps the durability of
J. S. LINDHOLT1 EVAR acceptable but with the general aging of the population, the
1 Vascular Research Unit, Viborg Hospital, Denmark durability of the aorta is not adequate?
References
AAA includes an asymptomatic phase with a relatively low-risk (1) EVAR Trial Participants. Comparison of endovascular aneurysm repair with
treatment, compared with the symptomatic phase, which is a good open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day
argument to consider screening. However, all criteria formulated by operative mortality results: randomised controlled trial. Lancet 2004; 364:843-
848.
the Council of Europe must be fulfilled; Ultrasonographic screening is
(2) Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm
a valid, suitable and acceptable method of screening as the estimated R et al. A randomized trial comparing conventional and endovascular repair of
sensitivity and specificity is 98% and 99%, respectively, acceptance abdominal aortic aneurysms. N Engl J Med 2004; 351:1607-1618.
rates are above 75%, and 95% accept control scans. The offer of (3) Lederle FA, Freischlag JA, Kyriakides TC, Padberg FT, Jr., Matsumura JS,
screening for AAA causes transient, mild reactions of fear, but repeated Kohler TR et al. Outcomes following endovascular vs open repair of abdominal
screening seems only required in 5% of the initially negative findings. aortic aneurysm: a randomized trial. JAMA 2009; 302:1535-1542.
Evidence based large scaled randomised trials have identified 5.5 cm (4) Blankensteijn JD, de Jong SE, Prinssen M, van der Ham AC, Buth J, van
as cut point for repairing asymptomatic AAA, and survivors enjoy the Sterkenburg SM et al. Two-year outcomes after conventional or endovascular
repair of abdominal aortic aneurysms. N Engl J Med 2005; 352:2398-2405.
same quality of life as the general population of the same age, and it
(5) EVAR Trial Participants. Endovascular aneurysm repair versus open repair in
seems that only 2-5% of patients refuse an offer of surgery. patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled
Finally, the benefits of screening must outweigh the costs. All four trial. Lancet 2005; 365:2179-2186.
existing randomised trials are reporting benefit of screening of men (6) The UK EVAR Trial Participants. Endovascular versus open repair of
aged 65 and above, and the pooled mid-term and long term relative risk abdominal aortic aneurysm. N Engl J Med 2010; 2010;362:1863-70.
reduction is both around 50%, and 2% reduction in overall mortality. (7) The UK EVAR Trial Participants. Endovascular repair of aortic aneurysm in
Cost effectiveness have proven attractive in the large MASS trial, and patients physically ineligible for open repair. N Engl J Med 2010; 362:1872-80
recently the Viborg Study reported after 14 years that the number needed
to screen to save one life was just 135, the frequency of emergency
operations due to rupture was significantly reduced by 56%. The cost
per life year gained could be calculated at 157€ and the cost per QALY

26 ~

Sy1-4 mediCaL apprOaCH tO tHe patieNt WitH Sy2-2 NeW StrateGieS tO imprOVe COmpLiaNCe
aN abdOmiNaL aOrtiC aNeUrySm OF COmpreSSiON tHerapy (20-36 mmHG)
F. BECKER1 D. RASTEL1, E. LE FLOCH2, B. LUN3
1 Division of Angiology and Hemostasis, Department of Internal 1 Grenoble, France
Medicine, University Hospitals of Geneva, Geneva, Switzerland 2 Paris, France
3 Saint-Just Saint-Rambert, France
Until recently, abdominal aortic aneurysm has only been seen through
an immutable progression and a very high mortality in case of rupture. Compression therapy (CT) is one of the key treatment of deep and
In this frame any AAA discovered was monitored by imaging as superficial venous disorders. CT based on Medical compression
long as the surgical benefit versus risk of rupture was in favor of a stockings (MCS) is generally preferred to bandages thanks to the
preventive surgery. The threshold diameter of the AAA being at better control of the delivered pressure. Nervertheless, it is admitted
50 mm. that the compliance to MCS remains insufficient due to difficulties to
Nevertheless, -firstly when analyzing the causes of death of patients put on, to wear and to remove MCS. In a recent survey among French
with AAA, the AAA rupture is not the main cause, it may even be the phlebologists (MCS with 20-36mmHg at the ankle; alias french class
last one, -secondly the operative mortality in scheduled surgery for 3), 21.4% of patients are uncompliant, 70.4% have difficulties to put on
AAA is largely due to pre-existing co-morbidities, -thirdly even if we and 25.4% feel discomfort.
have no evidence-based drug to slow the progression of AAA, actions Then, new strategies of research have been conducted to improve
against some reducible factors (like smoking and sedentariness) are compliance to MCS over long term periods of treatment such as it is
likely to slow the AAA progression rate. required to treat post thrombotic syndrome or severe venous pathologies.
Faced with a patient who has just been discovered a AAA <50 mm One of the key point for compliance is the putting on process where its
AP, we must not only monitor the evolution of AAA by scheduled main parameter is fabric friction factor at the level of the instep and the
ultrasound examinations, we must act on cardio-vascular risk factors ankle. So, the objectives of the strategy was to reduce friction.
and on co-morbidities that are able to exacerbate the potential surgical This was driven through different studies:
risk. In particular, smoking cessation, improvement of respiratory 1 - To improve our knowledges on skin-MCS interface, coefficent
function, regular exercise... are probably as important as the repeated of friction and secondary skin parameters. In brief, hydration
imagings. It is probably also useful to inquire about the relatives over (corneometer®), micro-structure (Visioscan®), water loss (Tewameter®),
50 years of the patient. elasticity (Cutometer®) have been measured.
2 - To optimise the ergonomic description of patients’ body movements
SY 2 - Efficient compression therapy to treat venous during putting on and pulling off processes, a biomechanician approach
diseases: scientific, medical and practical key factors have been considered. Muscle activities were investigated using surface
(Corporate Symposium - Sigvaris) electromyography measurements. We concluded that muscle activity
of the thumb is mainly involved in putting on and muscle groups of
Sy2-1 COmpreSSiON tHerapy iN CHrONiC VeNOUS shoulder in removing MCS.
diSOrderS: a briGHt FUtUre reQUiriNG maNy 2 - To facilitate the putting on process (slippy aspect), improvement
eFFOrtS (yarns selection) and innovation (dynamic in elasticity) in MCS
P. CARPENTIER1 concept and design were implemented («EXPERT» from SIGVARIS).
1 Centre de Recherche Universitaire de La Léchère (73210), France Conducted on a pannel of 30 patients in different situations (comparative
test) we noticed that for 79% putting on is improved and 93% felt
Although compression therapy is increasingly acknowledged as the confortable with this new MCS.
cornerstone of the treatment of patients with chronic venous disorders
(CVD), its use in everyday practice is far from satisfactory, and Sy2-3 COmpreSSiON aFter SCLerOtHerapy
many efforts have to be developed by the manufacturers, the vascular P. KERN1
scientists, the attending physicians and the patients in order to get the 1 Private office of vascular medicine in Vevey, Switzerland
potential benefit that can be drawn from this major therapeutic tool:
- Patients have to appropriate their compression device, to learn how to As recommended in the guidelines of the German Society of
use and to look after it, and to adapt in some way their lifestyle to the Phlebology most specialists apply compression after sclerotherapy
treatment, all objectives that are nothing short of difficult and require of saphenous varicose veins and collaterals. Applying an extrinsic
knowledge, skills and motivation, which means that compression selective compression associated with compression bandage after
therapy requires specific therapeutic education programs. sclerotherapy of the great saphenous vein significantly enhances results
- Physicians have to play their role in these therapeutic education at 2 years (echographic recanalisation 11 vs 23%, respectively)1. On
programs, and already the prescription process is one first important the contrary, short term (< 6 weeks) results and incidence of side
step for building motivation, insuring the adequacy of the device to effects are not influenced by compression (low grade 15-20 mmHg
the vascular status of the patient and for customizing it to its personal medical compression stocking (MCS)2, or 5 days instead of one day
needs: education of the physicians is also necessary. compression bandages3).
- A lot of work is needed from the vascular scientists who have yet In the setting of telangiectasias, several studies demonstrated a
to validate the efficacy of compression stockings in some important beneficial effect of wearing MCS after sclerotherapy. This was shown
indications such as venous edema, and to define the optimal pressure for telangiectasias greater than 0.5 mm in diameter4. The best effects
and stiffness for each clinical situation through adequate therapeutic were observed in patients wearing MCS 20-30 mmHg for three
trials, in order to make the use of compression stockings quite an weeks5. Recently, this benefit was confirmed by a prospective study6.
evidence-based practice. After one session of sclerotherapy for telangiectasias on the lateral
- The acceptability (esthetics, comfort, easiness to handle) and physical aspect of the thigh (C1A or SEPASPN1), 100 patients were randomized
properties of the compression have very much improved during the last either to daily 23-32 mmHg MCS for three weeks or no compression.
decade. However, a lot remains to be done from the manufacturers in Objective rating of vessel disappearance was significantly better
this respect, and they also have to play their role in the promotion of after compression (p= .026). Poor results were more frequent in the
the therapeutic trials. no compression group (43% versus 24%). Micro-thrombi were less
All these efforts, and their coordination, are necessary to make prevalent in the compression group. Finally, a subsequent study7,
compression therapy more effective in real life. comparing 1 to 4 week MCS, showed a significant reduction of post-


Eurochap2010 final program

Empfohlen

Empfohlen

Weitere ähnliche Inhalte

Andere mochten auch

Andere mochten auch (18)

Ähnlich wie Eurochap2010 final program

Ähnlich wie Eurochap2010 final program (16)

Mehr von sfa_angeiologie

Mehr von sfa_angeiologie (20)

Eurochap2010 final program